Skip to main content
. 2009 Nov 18;9:85. doi: 10.1186/1471-230X-9-85

Table 1.

Baseline and Descriptive Characteristics

Group Gas Defense
(n = 30)
Placebo
(n = 31)
Site
 Dominican Republic 27 (90%) 27 (87%)
 Miami, FL 3 (10%) 4 (4%)

Age, Years 34.8 ± 12.5 38.2 ± 12.6

Gender
 Female 16 (53%) 17 (55%)
 Male 14 (47%) 14 (45%)

Ethnicity
 Hispanic 27 (90%) 28 (90%)
 Non-Hispanic 3 (10%) 3 (10%)

Race
 Black/AA 8 (27%) 7 (23%)
 Caucasian 9 (30%) 9 (29%)
 Other 12 (43%) 15 (48%)

Height, cm 164.2 ± 8.6 165.8 ± 9.8

Weight, kg 71.4 ± 14.1 79.2 ± 19.3

Status
 Completed Protocol 30 (100%) 30 (97%)
 Early Termination 0 (0%) 1 (3%)

Heart Rate, beats/minute 69.9 ± 12.1 70.7 ± 10.3

Systolic Blood Pressure, mm Hg 121.2 ± 17.0 122.2 ± 10.9

Diastolic Blood Pressure, mm Hg 75.1 ± 9.0 76.0 ± 7.2

GSRS - Abdominal Pain Subscore 3.17 ± 1.85 3.14 ± 1.48

GSRS - Abdominal Distension Subscore 3.38 ± 2.13 4.14 ± 1.43

GSRS - Increased Flatus Subscore 3.86 ± 1.92 4.07 ± 1.53

GSRS - Total GI Symptom Score 40.8 ± 19.8 39.4 ± 12.1

SODA - Bloating Subscore 2.52 ± 1.48 2.93 ± 1.25

SODA - Gas Subscore 3.28 ± 0.96 3.28 ± 0.84

SODA - Non-pain Symptoms Score 16.83 ± 3.35 17.00 ± 2.09

SODA - Satisfaction Score 8.3 ± 3.4 9.2 ± 3.5

SF-36v2 - Physical Component Summary 49.9 ± 8.5 49.0 ± 9.9

SF-36v2 - Mental Component Summary 51.3 ± 10.1 51.3 ± 9.9

Values are expressed as mean ± standard deviation.